Interesting analogy@Taureanbull But perhaps not as far fetched...

Interesting analogy@Taureanbull But perhaps not as far fetched as some may think...

Step 1. Buy a manufacturing plant to make your products and have the plant approved by the FDA

Done

Step 2. Start marketing azer cel in the blood cancer market via the registrational trial route in late 2024

Data Bridge Market Research analyses that the blood cancer market was valued at USD 43.71 billion in 2021 and is expected to reach USD 89.68 billion by 2029, registering a CAGR of 9.40% during the forecast period of 2022 to 2029.

Step 3. Work in conjunction with CF33/Vaxinia via the Phase 2 registrational trial route as early as 2025

Data Bridge Market Research analyses that the solid tumors market was valued at USD 209.61 billion in 2021 and is expected to reach USD 901.27 billion by 2029, registering a CAGR of 20.0% during the forecast period of 2022 to 2029.

Step 4. Join the dots

Todays Announcement

Beyond using azer-cel in blood cancers, in the future it will also be combined with Imugene’s own onCARlytics for treatment of patients with solid tumours, opening a potentially large market for azer-cel in the 90% of oncology not beyond blood cancers

Professor Yuman Fong killed all cancers against the NCI60 with CF33/Vaxinia pre clinically. The overall cancer market of an estimated 990BM USD market size is within Imugene's reach should the ongoing Vaxinia Trial at higher dose rates go to plan.

Step 5. Do the maths on that at 4-5 times peak earnings and sit back and watch this space

DYOR Seek investment advice as and when required Opinions only